All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub was pleased to speak to Vania Tietsche de Moraes Hungria, Clínica São Germano, São Paolo, BR. We asked: What factors influence the adoption rates of novel multiple myeloma (MM) therapies in Latin America?
What factors influence the adoption rates of novel MM therapies in Latin America?
In this video interview, Vania Hungria provides an overview of the MM landscape in Latin America, focusing on the differences in access and adoption of novel therapies in public and private health care facilities. Hungria discusses the distribution of treatment between public and private institutions and the outcomes associated with treatment in each type of center.
Subscribe to get the best content related to multiple myeloma delivered to your inbox